SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 alpha-REDUCTASE ISOZYME ENZYMATIC ACTIVITY IN THE HUMAN PROSTATE
- 1 January 1999
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 161 (1) , 332-337
- https://doi.org/10.1016/s0022-5347(01)62141-4
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Prostate Tissue Composition and Response to Finasteride in Men With Symptomatic Benign Prostatic HyperplasiaJournal of Urology, 1997
- Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasiaClinical Endocrinology, 1997
- Characterization of 5α-reductase gene expression in stroma and epithelium of human prostateThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- The Concentrations of the Endogenous C19-Steroids in Hyperplastic Prostatic Tissue and the Effect of Finasteride TreatmentHormone and Metabolic Research, 1996
- Kinetic analysis of steroid 5α-reductase activity at neutral pH in benign prostatic hyperplastic tissue: Evidence for type I isozyme activity in the human prostateThe Journal of Steroid Biochemistry and Molecular Biology, 1996
- In Vivo Time-Dependent Inhibition of Human Steroid 5a-Reductase by FinasterideJournal of Pharmaceutical Sciences, 1996
- Immunocytochemical localization of human 5 alpha-reductase 2 with polyclonal antibodies in androgen target and non-target human tissues.Journal of Histochemistry & Cytochemistry, 1994
- 17.beta.-(N-tert-Butylcarbamoyl)-4-aza-5.alpha.-androstan-1-en-3-one Is an Active Site-Directed Slow Time-Dependent Inhibitor of Human Steroid 5.alpha.-Reductase 1Biochemistry, 1994
- Benign prostatic hyperplasia and normal prostate aging: differences in types I and II 5 alpha-reductase and steroid hormone receptor messenger ribonucleic acid (mRNA) levels, but not in insulin-like growth factor mRNA levelsJournal of Clinical Endocrinology & Metabolism, 1993
- Finasteride: A slow-binding 5.alpha.-reductase inhibitorBiochemistry, 1993